Search

Your search keyword '"Anand, Sarah"' showing total 166 results

Search Constraints

Start Over You searched for: Author "Anand, Sarah" Remove constraint Author: "Anand, Sarah"
166 results on '"Anand, Sarah"'

Search Results

3. Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions

4. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

5. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors

7. Incidence of Restrictive Lung Disease Following Autologous Stem Cell Transplantation for High Risk Lymphoma

8. Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation to Mitigate Acute Graft Versus Host Disease: A Phase II Study Clinical Update

9. MODULAATE (Part 1): An Open-Label, Dose-Finding Phase 2 Evaluation of Alpha-1 Antitrypsin for the Prevention of Graft-Versus-Host Disease in Patients Receiving Hematopoietic Cell Transplantation

10. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.

11. Heightened TLR7 Primes BCR-Activated Cells in Chronic Graft-Versus-Host Disease for Effector Functions

13. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

14. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant

16. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease

17. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD

21. Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients

22. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

23. Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

24. A secondary CD34+ acute lymphoblastic leukemia unmasked and mobilized by G‐CSF in an autologous stem cell donor with testicular cancer.

25. DIRECTOR-LED INVESTIGATIONS

27. MODULAATE, A 2-Part, Dose-Finding, Efficacy and Safety Trial with Alpha-1 Antitrypsin (AAT) for Prevention of Acute Graft vs. Host Disease (aGVHD): Part 1 Safety and Pharmacokinetic (PK) Results

28. Use of Siltuximab for the Treatment of Severe Immune Effector Cell Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy: Single Center Case Series

32. Characterizing advance care planning, palliative care utilization, and location of end-of-life for adult allogeneic hematopoietic stem cell transplant recipients.

33. BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation

34. Safety Analysis of Patients Who Received Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease in an Expanded Access Program

35. Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus-Host Disease

36. Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study)

37. Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study

38. Evaluation of the Oral SYK Inhibitor Fostamatinib in Patients after Allogeneic Transplantation for Chronic Graft-Versus-Host Disease

42. Ultrasensitive Genomic Minimal Residual Disease Detection in Peripheral Blood after Allogeneic HSCT for MDS Is Associated with Increased Relapse Risk and Inferior Survival

43. Impact of Individual Vs. Composite Endpoints for Prediction of Long-Term Survival in Gvhd Clinical Trials Research

44. The Effect of Azithromycin on Relapse in Patients with Moderate-Severe Chronic Graft Versus Host Disease (CGVHD)

45. Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease

47. Increased TLR7 Signaling of BCR-Activated B Cells in Chronic Graft-Versus Host Disease (cGVHD)

49. Recipient-Derived BAFF and Alloantigen Synergistically Activate B Cells in Murine Chronic Gvhd

50. All-Trans Retinoic Acid (ATRA) Targets IRF4 Deficient, NOTCH2-Activated B Cells from Chronic Gvhd Patients

Catalog

Books, media, physical & digital resources